POLICY AND ADVOCACY INITIATIVES

Protecting Massachusetts’ status as the best place
in the world for biotech

Through education and advocacy, MassBio promotes thoughtful legislative and regulatory solutions that give Massachusetts life sciences companies the best environment possible to research, develop, and commercialize breakthrough therapies and cures, and that ensure patients around the world have equitable, affordable access to those new treatments. Likewise, we oppose policies that threaten patient access, limit innovation, or hurt the Massachusetts life sciences industry’s competitiveness in the global economy.

When government, industry, and academia work together, our industry thrives and patients around the world benefit. MassBio is here to ensure that the relationship is strong, lasting, and mutually beneficial.

Policy News & Legislative Updates

MassBio regularly issues statements about our position on a variety of state and federal policy proposals that impact our industry, our members, and patients. In addition, every week we summarize what happened at the State House and on Capitol Hill, while looking forward at the week ahead in our Legislative Updates.

The Massachusetts Biotech Caucus

The Massachusetts State Legislative Biotech Caucus is a group of state legislators interested in and supportive of the life sciences industry. Caucus meetings may include company site visits, panel discussions on hot topics, or educational programs. By sharing information and resources with the Caucus Co-Chairs, MassBio helps inform the Caucus’ activities and educational opportunities.

Contact Susan Martin to learn more.

Policy Working Group

MassBio convenes a Policy Working Group of member company government affairs leads and key company contacts who meet regularly to discuss and formulate MassBio’s state and federal advocacy strategy. Inclusion in the Policy Working Group is by invitation only.

Contact Susan Martin to learn more.

Legislative Priorities

Our approach to legislative advocacy is driven by two aligned missions: protecting patient access to existing and future therapies; and, ensuring Massachusetts remains the best place in the world for life sciences companies to thrive. State and federal policy priorities are developed by MassBio’s government relations team in close consultation with our member companies through the Policy Working Group and other industry stakeholders.

State Priorities

Massachusetts is the world leader in life sciences innovation. We also lead in healthcare policy and access to high quality healthcare and breakthrough therapies. That’s why it’s critical we educate and inform state legislators as they make decisions that impact our ecosystem. Our state advocacy focuses on issues such as: commercial and Medicaid access and reimbursement, the proper use of health technology assessments (HTAs), co-pay assistance programs, transportation, housing, workforce development, and diversity & inclusion.

2021-2022 State Legislation

This will be updated as legislation is introduced in the 2021 session that is pertinent to the life sciences industry.

Federal Priorities

MassBio consistently works to promote a regulatory and legislative environment that enables the life sciences industry to thrive. MassBio has established long-lasting relationships with both lawmakers and regulators in Washington DC and continues to advocate for policies and initiatives on behalf of the industry. Our federal advocacy focuses on a range of issues from: access to reimbursement, paying for value, tax reform, workforce development, immigration, NIH funding, and the regulatory environment.

Federal Legislation

Most Favored Nation Rule (Trump Administration)

In November, President Trump announced an interim final rule regarding the administration’s “most favored nations” policy which seeks to tie prescription drug prices in Medicare to those in international, developed countries. Because the legislation was announced as an interim final rule, this enabled the Trump Administration to bypass normal regulatory processes and forgo additional public comment before going into effect immediately.

MassBio Position: Oppose. MassBio does not support any initiatives to tie prescription drug prices to those in foreign countries. Legislation of this nature is extremely harmful and serves to limit patient access to breakthrough therapies. Read MassBio’s statement on the Most Favored Nation Rule here.

Current Status: The Biotechnology Innovation Organization (BIO), California Life Sciences Association (CLSA), and BIOCOM California filed a lawsuit challenging the plan, and the United States District Court of Northern California granted an injunction, which effectively blocked the implementation of the rule until it proceeded with a formal notice and comment rulemaking. In January 2020, the Justice Department decided not to challenge the injunction.